These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

388 related articles for article (PubMed ID: 31455608)

  • 1. Faecal haemoglobin concentration among subjects with negative FIT results is associated with the detection rate of neoplasia at subsequent rounds: a prospective study in the context of population based screening programmes in Italy.
    Senore C; Zappa M; Campari C; Crotta S; Armaroli P; Arrigoni A; Cassoni P; Colla R; Fracchia M; Gili F; Grazzini G; Lolli R; Menozzi P; Orione L; Polizzi S; Rapi S; Riggi E; Rubeca T; Sassatelli R; Visioli C; Segnan N
    Gut; 2020 Mar; 69(3):523-530. PubMed ID: 31455608
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Faecal haemoglobin can define risk of colorectal neoplasia at surveillance colonoscopy in patients at increased risk of colorectal cancer.
    Digby J; Cleary S; Gray L; Datt P; Goudie DR; Steele RJC; Strachan JA; Humphries A; Fraser CG; Mowat C
    United European Gastroenterol J; 2020 Jun; 8(5):559-566. PubMed ID: 32213041
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Performance of two faecal immunochemical tests for the detection of advanced neoplasia at different positivity thresholds: a cross-sectional study of the Dutch national colorectal cancer screening programme.
    de Klerk CM; Wieten E; Lansdorp-Vogelaar I; Bossuyt PM; Spaander MC; Dekker E
    Lancet Gastroenterol Hepatol; 2019 Feb; 4(2):111-118. PubMed ID: 30497962
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Guaiac-based faecal occult blood tests versus faecal immunochemical tests for colorectal cancer screening in average-risk individuals.
    Grobbee EJ; Wisse PHA; Schreuders EH; van Roon A; van Dam L; Zauber AG; Lansdorp-Vogelaar I; Bramer W; Berhane S; Deeks JJ; Steyerberg EW; van Leerdam ME; Spaander MC; Kuipers EJ
    Cochrane Database Syst Rev; 2022 Jun; 6(6):CD009276. PubMed ID: 35665911
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term performance of colorectal cancerscreening programmes based on the faecal immunochemical test.
    Zorzi M; Hassan C; Capodaglio G; Fedato C; Montaguti A; Turrin A; Rosano A; Monetti D; Stocco C; Baracco S; Russo F; Repici A; Rugge M
    Gut; 2018 Dec; 67(12):2124-2130. PubMed ID: 29101260
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Faecal haemoglobin concentration is related to detection of advanced colorectal neoplasia in the next screening round.
    Digby J; Fraser CG; Carey FA; Diament RH; Balsitis M; Steele RJ
    J Med Screen; 2017 Jun; 24(2):62-68. PubMed ID: 27370211
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multiple rounds of one sample versus two sample faecal immunochemical test-based colorectal cancer screening: a population-based study.
    Schreuders EH; Grobbee EJ; Nieuwenburg SAV; Kapidzic A; van Roon AHC; van Vuuren AJ; Lansdorp-Vogelaar I; Spijker WWJ; Izelaar K; Bruno MJ; Kuipers EJ; Spaander MCW
    Lancet Gastroenterol Hepatol; 2019 Aug; 4(8):622-631. PubMed ID: 31196734
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Detection of advanced colorectal neoplasia and relative colonoscopy workloads using quantitative faecal immunochemical tests: an observational study exploring the effects of simultaneous adjustment of both sample number and test positivity threshold.
    Young GP; Woodman RJ; Symonds E
    BMJ Open Gastroenterol; 2020 Sep; 7(1):. PubMed ID: 32994195
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Population-based colorectal cancer screening programmes using a faecal immunochemical test: should faecal haemoglobin cut-offs differ by age and sex?
    Arana-Arri E; Idigoras I; Uranga B; Pérez R; Irurzun A; Gutiérrez-Ibarluzea I; Fraser CG; Portillo I;
    BMC Cancer; 2017 Aug; 17(1):577. PubMed ID: 28851318
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Faecal haemoglobin concentration influences risk prediction of interval cancers resulting from inadequate colonoscopy quality: analysis of the Taiwanese Nationwide Colorectal Cancer Screening Program.
    Chiu SY; Chuang SL; Chen SL; Yen AM; Fann JC; Chang DC; Lee YC; Wu MS; Chou CK; Hsu WF; Chiou ST; Chiu HM
    Gut; 2017 Feb; 66(2):293-300. PubMed ID: 26515543
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunochemical faecal occult blood testing to screen for colorectal cancer: can the screening interval be extended?
    Haug U; Grobbee EJ; Lansdorp-Vogelaar I; Spaander MCW; Kuipers EJ
    Gut; 2017 Jul; 66(7):1262-1267. PubMed ID: 27006184
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Faecal haemoglobin concentration in adenoma, before and after polypectomy, approaches the ideal tumour marker.
    Mowat C; Digby J; Cleary S; Gray L; Datt P; Goudie DR; Steele RJ; Strachan JA; Humphries A; Fraser CG
    Ann Clin Biochem; 2022 Jul; 59(4):272-276. PubMed ID: 35235491
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of a higher fecal immunochemistry test cut-off on pathology detected in subsequent rounds of a colorectal screening program.
    Gibson DJ; Mooney T; Mooney J; Mulcahy HE; O'Donoghue D
    Gastrointest Endosc; 2019 Mar; 89(3):518-522. PubMed ID: 30142350
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interval cancers using a quantitative faecal immunochemical test (FIT) for haemoglobin when colonoscopy capacity is limited.
    Digby J; Fraser CG; Carey FA; Lang J; Stanners G; Steele RJ
    J Med Screen; 2016 Sep; 23(3):130-4. PubMed ID: 26589788
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fecal immunochemical test in colorectal cancer screening: Colonoscopy findings by different cut-off levels.
    Ribbing Wilén H; Blom J; Höijer J; Hultcrantz R
    J Gastroenterol Hepatol; 2019 Jan; 34(1):103-112. PubMed ID: 29968937
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Faecal immunochemical tests versus colonoscopy for post-polypectomy surveillance: an accuracy, acceptability and economic study.
    Atkin W; Cross AJ; Kralj-Hans I; MacRae E; Piggott C; Pearson S; Wooldrage K; Brown J; Lucas F; Prendergast A; Marchevsky N; Patel B; Pack K; Howe R; Skrobanski H; Kerrison R; Swart N; Snowball J; Duffy SW; Morris S; von Wagner C; Halloran S
    Health Technol Assess; 2019 Jan; 23(1):1-84. PubMed ID: 30618357
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of time between faecal immunochemical tests in colorectal cancer screening on screening results: A natural experiment.
    Ribe SG; Botteri E; Løberg M; Randel KR; Kalager M; Nilsen JA; Gulichsen EH; Holme Ø
    Int J Cancer; 2023 Apr; 152(7):1414-1424. PubMed ID: 36346118
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomised comparison of two faecal immunochemical tests in population-based colorectal cancer screening.
    Grobbee EJ; van der Vlugt M; van Vuuren AJ; Stroobants AK; Mundt MW; Spijker WJ; Bongers EJC; Kuipers EJ; Lansdorp-Vogelaar I; Bossuyt PM; Dekker E; Spaander MCW
    Gut; 2017 Nov; 66(11):1975-1982. PubMed ID: 27507905
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Choice of faecal immunochemical test matters: comparison of OC-Sensor and HM-JACKarc, in the assessment of patients at high risk of colorectal cancer.
    Chapman CJ; Banerjea A; Humes DJ; Allen J; Oliver S; Ford A; Hardy K; Djedovic N; Logan RF; Morling JR
    Clin Chem Lab Med; 2021 Mar; 59(4):721-728. PubMed ID: 33112776
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Equivalency of fecal immunochemical tests and colonoscopy in familial colorectal cancer screening.
    Quintero E; Carrillo M; Gimeno-García AZ; Hernández-Guerra M; Nicolás-Pérez D; Alonso-Abreu I; Díez-Fuentes ML; Abraira V
    Gastroenterology; 2014 Nov; 147(5):1021-30.e1; quiz e16-7. PubMed ID: 25127679
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.